TrialBritish journal of clinical pharmacology2013

First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials.

Joerg J Moehrle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.